Atossa Genetics Inc. (ATOS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATOS Stock Price Chart Interactive Chart >
ATOS Price/Volume Stats
| Current price | $0.73 | 52-week high | $1.42 |
| Prev. close | $0.69 | 52-week low | $0.50 |
| Day low | $0.71 | Volume | 209,376 |
| Day high | $0.74 | Avg. volume | 471,207 |
| 50-day MA | $0.74 | Dividend yield | N/A |
| 200-day MA | $0.84 | Market Cap | 91.80M |
Atossa Genetics Inc. (ATOS) Company Bio
Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Latest ATOS News From Around the Web
Below are the latest news stories about ATOSSA THERAPEUTICS INC that investors may wish to consider to help them evaluate ATOS as an investment opportunity.
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate UpdateSEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced financial results for the fiscal quarter and fiscal year ended December 31, 2022 and provided an update on recent company developments. Key developments from Q4 2022 and year to date include: Initiation and First Patient Dosed in Phase 2 EVANGELINE Study – EVANGELI |
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical TrialAtossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, and Quantum Leap Healthcare Collaborative™ today announce that Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I-SPY 2 clinical trial. The I-SPY 2 TRIAL evaluates neoadjuvant treatments for locally advanced breast cancer and is a collaborati |
Atossa to Present at the Sidoti Small-Cap Virtual ConferenceSEATTLE, March 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced that the Company will present at the Sidoti Small-Cap Virtual Conference being held March 22-23, 2023. The presentation by Dr. Steven Quay, President and Chief Executive Officer and Kyle Guse, General Counsel and Chief Financial Officer, will take place on Thursday |
Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast CancerSEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces that the first patient has been dosed in the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study. EVANGELINE is a randomized non-inferiority trial of Atossa’s patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goser |
Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for EndoxifenSEATTLE, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces that the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,572,334) directed to (Z)-endoxifen encapsulated in an enteric capsule. This patent further reinforces Atossa’s broad Intellectual Property portfolio related to (Z)-endoxifen. |
ATOS Price Returns
| 1-mo | -1.35% |
| 3-mo | 38.13% |
| 6-mo | -12.40% |
| 1-year | -44.70% |
| 3-year | -38.14% |
| 5-year | -86.48% |
| YTD | 38.13% |
| 2022 | -66.97% |
| 2021 | 68.42% |
| 2020 | -39.49% |
| 2019 | 53.92% |
| 2018 | -67.68% |
Loading social stream, please wait...